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Abstract
Background: The impact of variation of Epstein-Barr virus (EBV) antibody titers before the development of nasopharyngeal
carcinoma (NPC) is still unclear. We analyzed the fluctuations of antibodies against EBV before histopathological diagnosis
to assess the risk of NPC and aimed to provide a reliable basis for screening in high risk populations.
Methods: This study was based on a population-based screening program in Sihui County in Guangdong Province of China.
A total of 18,986 subjects were recruited in 1987 and 1992, respectively. Baseline and repeated serological tests were
performed for IgA antibodies against EBV capsid antigen (VCA/IgA) and early antigen (EA/IgA). Follow-up until the end of
2007 was accomplished through linkage with population and health registers. Cox proportional hazards regression model
was used to estimate the relative risk of NPC in association with EBV antibodies. Time-dependent receiver operating
characteristic curve (ROC) analysis was used to further evaluate the predictive ability.
Results: A total of 125 NPCs occurred during an average of 16.9 years of follow-up. Using baseline information alone or
together with repeated measurements, serological levels of VCA/IgA and EA/IgA were significantly associated with
increased risks for NPC, with a striking dose-response relationship and most prominent during the first 5 years of follow-up.
Considering the fluctuant types of serological titers observed during the first three tests, relative risk was highest among
participants with ascending titers of EBV VCA/IgA antibodies with an adjusted hazard ratio (HR) of 21.3 (95% confidence
interval [CI] 7.1 to 64.1), and lowest for those with decreasing titers (HR=1.5, 95% CI 0.2 to 11.4), during the first 5 years of
follow-up. Time-dependent ROC analysis showed that VCA/IgA had better predictive performance for NPC incidence than
EA/IgA.
Conclusion: Our study documents that elevated EBV antibodies, particularly with ascending titers, are strongly associated
with an increased risk for NPC.
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Introduction
Nasopharyngeal carcinoma (NPC) is a rare malignancy in most
populations of the world, with incidence rates lower than 1 per
100,000 person-years [1]. However, among populations in the
southern parts of China and Southeast Asia, where NPC is more
endemic than any parts of the world,the incidence rates areas highas
20 to 50 per 100,000 person-years, especially in Cantonese-speaking
men residing in Guangdong Province and Hong Kong of Southern
China [1–5]. Salted-fish consumption [6–10], Epstein-Barr virus
(EBV) infection [11–19] and genetic susceptibility [20–23] are
considered to be the major risk factors that contribute to such a
distinguished geographic distribution for this cancer.
Although it has not been addressed thoroughly, several pieces of
evidence suggest that EBV infection is strongly associated with the
occurrence of NPC, especially the undifferentiated subtype of non-
keratinising carcinoma [14], the most common histopathological
type in southern China according to WHO classification [24]. As
early as in 1966, elevation of antibodies against EBV antigens in
NPC patients was observed [25]. In 1973, presence of EBV
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19100genomes was demonstrated in epithelial NPC cells [18] and EBV-
related antigens were detected in the tumor cells of all NPC
patients [26]. Subsequently, the expression of the viral genome in
non-keratinising NPC has been studied extensively in areas with
NPC epidemic [14,16,27] and major types of viral expression
proteins have been found, e.g., EBNA1 [28–30], LMP1 [15,31–
34] and LMP2A [31]. Moreover, in case-control studies, NPC
cases showed significantly higher antibody titers to EBV antigens
than controls in several retrospective studies [11,19,35–38].
However, in these studies, serological results were mainly based
on blood specimens collected after the diagnosis of NPC, thus
these findings might not clarify the critical issue of EBV replication
in relation to occurrence of NPC. To avoid the concern of
potential reversal causality, blood samples should be collected long
time before clinical evidence appears.
To our knowledge, to date three prospective population-based
studies, which were based in Guangxi province, Zhongshan City
and Taiwan [39–45], have been conducted to explore the relation
between EBV antibodies and NPC onset. Findings from these
studies suggest that IgA antibodies against EBV capsid antigen
(VCA/IgA) is a biomarker associated with the risk of NPC
development and using this marker as a screening tool for NPC is
feasible [43–44,46–47]. Moreover, IgA antibody against EBV
early antigen (EA/IgA) is a highly specific marker, which is usually
assayed simultaneously with VCA/IgA for the diagnosis of NPC
[48–50]. Although the previous studies have several advantages,
the dose-response relationship between EBV antibody titers and
NPC risk is not yet clear. In fact, antibody levels are always
changing during the progression of NPC, however, the association
between fluctuant pattern of EBV antibodies and NPC risk has not
been explored. Further, the predictive abilities of these markers in
population cohort have not been reported. Moreover, it is possible
that seronegative subjects go through seroconversion before NPC
develops, but data regarding this issue are still lacking.
To further evaluate the relationship between EBV infection and
NPC risk, we used repeated serological data from a large
prospective population-based screening study in Sihui County,
which is located along the Pearl River in Guangdong Province,
China,one of the high-riskareas of NPC. In 1987,a screening study
using antibodies against EBV as biomarkers was initiated, aiming at
improvingearlydetectionrateand reducingthemortalityrateofthe
cancer. Here we analyzed the results after a 20-year follow-up from
this cohort to clarify the role of EBV infection in relation to risk of
NPC in the high incidence area of Southern China, especially the
dose-response relationship and the serological antibody fluctuation
over time long time before NPC occurrence.
Results
After 301,933 person-years of follow-up, 125 cases of incident
NPC were identified one year after recruitment into the study
cohort (Table 1), which rendered an age-adjusted incidence rate of
68.0 per 100,000 person-years for males and 25.0 per 100,000
person-years for females. The overall baseline sero-prevalence
rates of VCA/IgA and EA/IgA antibodies were 7.16% (1,318/
18,411) and 0.24% (45/18,411), respectively. The age-adjusted
incidence rate of NPC per 100,000 person-years was 29.4 among
subjects seronegative for VCA/IgA, 188.2 among those seropos-
itive for VCA/IgA but seronegative for EA/IgA, and 617.4 among
those seropositive for both markers.
Table 1. Baseline characteristics, crude and age-adjusted incidence rates (1/100,000 person-years) of nasopharyngeal carcinoma
(NPC) among 18,411 participants in the Sihui NPC screening cohort, Sihui, Guangdong, China (1987–2007).
Total subjects NPC patients Person-years
Crude-incidence rate
(1/100,000 person-years)
Age-adjusted incidence rate
(1/100,000 person-years)*
(n=18,411) (n=125) (n=301,933)
Gender
Male 7,078 79 115,712 68.3 68
Female 11,333 46 186,221 24.7 25
Age at entry
30–39 yr 8,653 49 144,634 33.9 –
40–49 yr 5,309 43 85,963 50.0 –
50–59 yr 4,449 33 71,336 46.3 –
Area of residence (town)
Longjiang 3,412 27 64,734 41.7 42.7
Jingkou 4,363 40 82,213 48.7 48.6
Jianggu 5,162 31 75,457 41.1 38.8
Didou 5,474 27 79,529 33.9 33.2
Status of serological tests at baseline{
VCA/IgA (2) 17,093 83 280,798 29.6 29.4
VCA/IgA (+)
EA/IgA (2) 1,262 38 20,300 187.2 188.2
EA/IgA (+) 45 4 671 596.3 617.4
Missing 11 0 164 0 0
*Standardized to the distribution of person-time experienced by the entire cohort (5-year age groups).
{After subjects were tested positive for IgA antibodies against EBV capsid antigen (VCA/IgA), tests for IgA antibodies against EBV early antigen (EA/IgA) were also
performed. Eleven subjects did not have enough sera for EA/IgA test.
doi:10.1371/journal.pone.0019100.t001
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risk indicator for NPC (Table 2). For attained follow-up duration
up to 5 years, compared with seronegative subjects, the adjusted
HRs were 6.7 (95% CI 2.7 to 16.3), 9.4 (95% CI 4.0 to 21.9), 22.5
(95% CI 8.6 to 59.1) and 41.9 (95% CI 16.0 to 110.2) for subjects
whose baseline VCA/IgA antibody titers were 1:5, 1:10, 1:20 and
$1:40, respectively. For attained follow-up duration more than
5 years, the HRs decreased but still showed a clear dose-response
relationship, with the corresponding HRs of 0.9 (95% CI 0.2 to
3.6), 6.4 (95% CI 3.2 to 13.2), 6.3 (95% CI 2.0 to 20.4) and 18.0
(95% CI 7.2 to 45.2), respectively. After 18 years of follow-up, the
cumulative probability of developing NPC was 34.6% for subjects
seropositive for VCA/IgA and 5.4% for those seronegative for
VCA/IgA, respectively (Figure 1). Among subjects seropositive for
Figure 1. Cumulative probability of developing nasopharyngeal carcinoma (NPC) during follow-up among 18,411 subjects,
according to baseline levels of IgA antibodies against EBV capsid antigen (VCA/IgA) (1987–2007).
doi:10.1371/journal.pone.0019100.g001
Table 2. Hazard ratios (HRs) and 95% confidence intervals (CIs) for nasopharyngeal carcinoma associated with baseline or
repeated levels of antibodies against Epstein-Barr virus antigens.
Serological status at baseline Entire cohort* Sub-cohort1
Num. of
subjects
Num. of
cases
Adjusted HRs (95% CIs) by attained follow-up
duration{ Adjusted HR (95% CIs)
#5 years .5 years
VCA/IgA (2) 17,093 83 1.0 (reference) 1.0 (reference) 1.0 (reference)
VCA/IgA (+)
1:5 585 8 6.7 (2.7, 16.3) 0.9 (0.2, 3.6) 3.7 (0.9, 16.0)
1:10 501 16 9.4 (4.0, 21.9) 6.4 (3.2, 13.2) 3.0 (0.7, 12.7)
1:20 144 8 22.5 (8.6, 59.1) 6.3 (2.0, 20.4) 11.2 (4.2, 29.8)
$1:40 88 10 41.9 (16.0, 110.2) 18.0 (7.2, 45.2) 32.6 (17.5, 60.8)
Combination of two markers
VCA/IgA EA/IgA{
1:5,1:10 (2) 1041 21 7.0 (3.4, 14.1) 2.8 (1.4, 5.5) 2.6 (0.8, 8.7)
1:5,1:10 (+) 37 3 48.1 (11.1, 209.0) 9.9 (1.4, 72.1) 19.3 (2.4, 157.7)
$1:20 (2) 221 17 27.8 (12.9, 59.9) 11.1 (5.3, 23.5) 16.1 (8.4, 30.9)
$1:20 (+) 8 1 88.7 (11.7, 673.3) N/AI 95.6 (44.4, 206.1)
*In this analyis, all 18,411 subjects were included, and only baseline serological information was used. HRs were adjusted for sex, age at entry (30–39, 40–49, 50–59
years) and residency by town.
{Since the proportional hazards assumption did not hold, results were presented separately by attained follow-up duration (#5v s.5 years).
{EA/IgA infomation from 11 subjects were missing, and these subjects were excluded from this analysis.
1This analysis included only 7890 subjects, who had at least two serological tests for VCA/IgA antibodies. Among them, 54 NPCs were identifid during follow-up. HRs
and 95%CIs were derived from time-dependent Cox proportional hazards regression model, adjusted for sex, age at entry (30–39, 40–49, 50–59 years) and residency by
town.
INo NPC was found in this stratum.
doi:10.1371/journal.pone.0019100.t002
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seropositive also for EA/IgA had significantly higher HRs
compared with those seronegative for EA/IgA, and the estimates
during the first 5 years of follow-up were consistently higher than
those after 5 years of follow-up (Table 2).
Using repeated serological results of 7,890 subjects in the course
of NPC screening and treating them as time-dependent variables
in the Cox regression model, the results were similar to those based
on baseline test only (Table 2). Subjects with highest VCA/IgA
titers ($1:40) had the highest adjusted HR (32.6, 95% CI 17.5 to
60.8) when compared with VCA/IgA baseline negative group. For
the group with titers of $1:20 for VCA/IgA and positive for EA/
IgA, compared with the group baseline seronegative for both
markers, the adjusted HR was as high as 95.6 (95% CI 44.4 to
206.1). In order to quantitatively measure fluctuation of antibody
titers and its effect on cancer outcome, we also treated baseline
measurement as constant variable, and the differences between
each repeated test and baseline measurement as time-varying
variables, adjusted for age, sex, and town. Results similarly
indicated that subjects with increasing serological titers for VCA/
IgA had a higher risk of developing NPC. Those subjects with one
unit of increase (equal to double the titers at baseline) or more
during follow-up rendered an adjusted HR of 12.4 (95% CI 5.4 to
28.5) compared with the category with stable VCA/IgA titers,
while the corresponding HR was 1.8 (95% CI 0.6 to 5.4) for less
than 1 unit of increase during follow-up.
Figure 2 shows the fluctuation of EBV VCA/IgA and EA/IgA
antibody titers over time by outcome among subjects seropositive
for VCA/IgA at baseline. Although both serological biomarkers
fluctuated over time, NPC group had consistently higher antibody
levels than those of NPC-free subjects. Among 962 participants
seropositive for VCA/IgA at baseline and with 3 or more tests,
129 participants were classified into Ascending group, and among
them 6 cases of NPC were detected, yielding an adjusted HR of
21.3 (95% CI 7.1 to 64.1) in the first 5 years of follow-up and 7.8
(95% CI 1.9 to 33.2) during the later follow-up duration,
compared with baseline seronegative participants. Among 426
subjects who belonged to Stable group, 11 cases of NPC were
identified, yielding an adjusted HR of 6.2 (95% CI 2.2 to 17.8) in
the first 5 years of follow-up and 5.5 (95% CI 2.5 to 12.2) in later
period of follow-up (Table 3). In contrast, the relative risks for
Descending group were much lower than the other two groups. In
the first 5 years of follow-up, the adjusted HR was only 1.5 and
statistically non-significant (Table 3).
Furthermore, 6,554 subjects seronegative in 1987 (or 1992)
baseline VCA/IgA test and free of NPC during follow-up were
retested for VCA/IgA antibodies in 1997. Among 438 subjects
who were seropositive for VCA/IgA in 1997, 6 subjects developed
NPC in the follow-up period from year 1998 to 2007. Whereas,
only 10 cases of NPC were found among 6,116 subjects who were
seronegative both in 1987 (or 1992) and 1997. The corresponding
HR for NPC in association with seroconversion to VCA/IgA
positivity was 9.0 (95% CI 3.2 to 24.8).
AUCs during follow-up from time-dependent ROC curve
analysis were shown in Figure 3. VCA/IgA showed good
predictive performance over the follow-up duration, and was
consistently better than EA/IgA. The sensitivity at 3
rd year of
follow-up for VCA/IgA was 66.7%, 50.1% and 33.4%, respec-
tively, when the cutoff value was set to 1:5, 1:10, or 1:20; the
corresponding specificity was 92.9%, 96.1% and 98.8%, respec-
tively. Compared with VCA/IgA, the sensitivity for EA/IgA was
lower, but the specificity was higher for different cutoff values
(Table S1). The AUC at 3
rd year was 0.807 for VCA/IgA and
0.541 for EA/IgA. The predictive ability of VCA/IgA in females
was consistently better than in males and did not vary importantly
by different age group (data not shown).
Discussion
This large population-based prospective serological screening
study conducted in the high risk area of NPC in Guangdong
province has confirmed the strong association between serological
EBVantibodymarkersandNPCrisk.Particularlyinthefirst5 years
of follow-up, a clear dose-response relationship between EBV
antibody titers and NPC risk was demonstrated. These results
indicated that the anti-EBV sero-markers are mainly short-term risk
predictors in the NPC development, although caution is needed
when interpreting results by follow-up duration because of lead time
bias, as baseline seropositive group was followed up much closer
than seronegative group. However, even after 5 years of follow-up
this association still existed, although the strength of association
decreased with follow-up duration. Our results are consistent with
previous reports. In several mass screening studies conducted in
Wuzhou and Cangwu, China [42–45], Zeng et al. reported that the
NPC annual incidence rate for VCA/IgA(+) persons was 2-fold to
81-fold the rate in age-group-matched general population. In
another study conducted in Taiwan [39–40,51], elevated VCA/IgA
and neutralizing antibodies against EBV DNAse were found to be
highly specific sero-markers for predicting NPC, with a 20-fold
increase in NPC risk for subjects seropositive for VCA/IgA
antibodies, and a 30-fold increase for those seropositive for both
biomarkers. Recently, a study conducted in Zhongshan City [41]
reported that subjects seropositive for VCA/IgA antibodies had a
relative risk of 5.8 for developing NPC, as compared with the
general screening population.
Although there is so far no evidence from randomized clinical
trial to support the screening of NPC using the EBV serological
Figure 2. Variation of IgA antibodies against Epstein-Barr virus
capsid (VCA/IgA) or early antigen (EA/IgA) over time in 42
subjects who developed nasopharyngeal carcinoma (NPC)
during follow-up and in 1,276 subjects who were NPC-free by
the end of follow-up, among the group baseline seropositive
for VCA/IgA (1,318 subjects). Note: Geometric means of serolgocial
titres in each follow-up year were calculated. Specifically, the numbers
of tests were 42, 37, 18, 19, 5, 16 and 11 for baseline, 1st year, 2nd year,
3rd year, 4th year, 5th year and 6th or more year of follow-up,
respectively in NPC group. The numbers of tests were 1276, 1217, 615,
813, 287, 1008 and 708 for baseline, 1st year, 2nd year, 3rd year, 4th
year, 5th year and 6th or more year of follow-up, respectively in NPC-
free group.
doi:10.1371/journal.pone.0019100.g002
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since the 1970’s in the southern China [43–44,53], and the two
markers of VCA/IgA and EA/IgA are most commonly used.
Correct interpretation of repeated test results and prediction of
NPC risk is important for providing clinical counseling, which is
critical for early detection and prognosis of the malignancy [54–
55]. To our knowledge, our study is the first to illustrate the
relationship between fluctuation of EBV seromarkers and NPC
outcomes. Those subjects with ascending VCA/IgA antibody
titers tended to have higher risks and shorter time to develop NPC,
compared to those with a descending pattern. Therefore, for these
patients, closer follow-up and rigorous clinical examination are
recommended.
The nature of the association between EBV and NPC is still
under debate. Persistent high titers of EBV-specific antibodies
could be the results of aberrant viral gene expression [56]. In our
study, seroconversion into VCA/IgA positive before NPC
development was observed. Further, in Zhongshan study [41], a
serologic window before NPC diagnosis when antibodies levels are
raised and sustained was also reported, with a mean duration of 37
months. These results suggest that positive seroconversion might
be a key step in the pathogenesis of NPC and the elevation of EBV
antibody titers may play an important role in the process of NPC
development.
Advantages of our study include the relatively large sample size
and a long-term follow-up. In addition, 96.8% (121/125) of NPC
cases were histopathologically confirmed. The unique information
of repeated tests enabled us to study the fluctuation of anti-EBV
sero-markers before the onset of NPC, which have not been
reported by previous studies. However, the current study still has
Table 3. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for nasopharyngeal carcinoma (NPC) by fluctuant type of
serological status during follow-up among 962 subjects seropositive for VCA/IgA antibodies against EBV capsid antigen compared
to 17,093 seronegative subjects at baseline*.
Serological status at baseline No. of subjects No. of cases Adjusted HRs (95% CIs){
Attained follow-up duration{
#5 years .5 years
VCA/IgA (2) 17,093 83 1.0 (reference) 1.0 (reference)
VCA/IgA (+)
Ascending 129 6 21.3 (7.1, 64.1) 7.8 (1.9, 33.2)
Stable 426 11 6.2 (2.2, 17.8) 5.5 (2.5, 12.2)
Descending 407 6 1.5 (0.2, 11.4) 2.9 (1.2, 7.4)
*Among the totally 1318 subjects seropositive for VCA/IgA antibodies at baseline, 356 had fewer than 2 repeated tests. Thus these subjects could not be classified into
any fluctuant group, thus were excluded from current analysis. Among them, 19 NPC cases were indentified.
{Adjusted for sex, age at entry (30–39, 40–49, 50–59 years) and residency by town.
{Since the proportional hazards assumption did not hold, results were presented separately by attained follow-up duration (#5v s.5 years).
doi:10.1371/journal.pone.0019100.t003
Figure 3. Time-dependent ROC curve analysis for nasopharyngeal carcinoma (NPC) prediction according to baseline levels of IgA
antibodies against EBV capsid antigen (VCA/IgA) and early antigen (EA/IgA) (ordinal categorical variable). ROC, receiver operating
characteristic; AUC, area under the ROC curve, NPC, nasopharyngeal carcinoma.
doi:10.1371/journal.pone.0019100.g003
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of other environmental risk factors, which precluded the
possibilities for controlling the potential confounding effects from
these risk factors. In addition, this study was conducted in a high-
risk area, and our results might not be applicable to other areas
with medium or low risk for NPC. Last, although this study is up to
date the largest, the small number of NPC cases made estimates in
some strata imprecise.
In conclusion, titers of antibodies against EBV may represent
the level of EBV replication. VCA/IgA and EA/IgA antibodies
are useful seromarkers for NPC screening in high risk areas. In
future NPC screening programs, close monitoring of subjects
seropositive for VCA/IgA antibodies are highly recommended.
Materials and Methods
Study Population
In 1987, the Chinese National Programs for Science and
Technology Development during the Seventh Five-Year Plan
Period of China was firstly launched in two towns from Sihui
County located in Guangdong province in the southern China,
which aimed at improving early detection of NPC through
serological screening tests for VCA/IgA and EA/IgA. During the
period of National Eighth Five-Year Plan, we extended our
research areas to four towns (Figure 4). Staff in Sihui Cancer
Institute and local village committee advertised and invited the
residents to attend this screening program. The inclusion criteria
were those who were Cantonese, residing in Sihui County, without
recorded history of NPC and with good physical condition and
mental health. The exclusion criteria were those who had severe
cardiovascular, liver or kidney diseases, with a recorded NPC or
not residing in Sihui County. Finally, 18,986 subjects, ages 30–59,
were voluntarily recruited in 1987 and 1992, respectively from
four towns of the Sihui County.
Medical staff from Sun Yat-sen University Cancer Center
(SYSUCC), Sihui Cancer Institute and local hospitals formed
research teams and visited the four towns, including Didou,
Jianggu, Longjiang and Jingkou, to collect subjects’ general socio-
demographic information (birthday, gender, occupation, marital
status, etc.) and blood samples. Written protocol documents had
been sent to each local screening towns and villages. The local
health of bureau and village committees have approved this
screening (including using oral informed consents). All regional
hospitals, village clinics and residents were informed about the
details of the study and participating in this screening program was
voluntary. Normally, the residents did not have any physical
examinations before participating this screening program. Since
Chinese Government did not require written informed consent
before 1999, and a lot of local residents could not read written
documents, oral informed consents were obtained instead.
Serological test for VCA/IgA was first performed. If the result
was positive, the serological test for EA/IgA was further
introduced. We also offered medical services such as otorhinolar-
yngologic and neck lymphatic examinations to the participants. If
we found abnormal conditions, such as tubercle, coarse voice,
ulcer in the nasopharynx, enlarged lymph nodes in the upper part
of neck or serological tests of obvious abnormalities, fiberoptic
endoscopy and pathological biopsy were performed by otorhino-
laryngologists to diagnose NPC.
Eleven cases of NPC had been diagnosed several years before
screening, 15 cases were newly found, and 4 cases were detected
within one year after recruitment. Moreover, 11 subjects had less
than 1 year of follow-up, and 228 subjects were lost to follow-up
since entry. The other 306 subjects were removed due to poor
quality of blood samples. Therefore, 575 subjects were excluded,
leaving a total of 18,411 subjects for the final cohort. In year 1997,
we re-contacted all subjects in this cohort to conduct serological
tests. However, 8 subjects moved out of Sihui County. 143 died of
diseases, accidents or unknown causes, 51 cases of NPC were
identified during follow-up, and 11,068 subjects declined to
participate. Finally, 7,141 subjects free of NPC were included in
this re-test.
Ethics Statement
Our study group had strictly abided by the principles of Helsinki
Declaration and International Ethical Guidelines for Biomedical
Research Involving Human Subjects developed by the Council for
International Organizations of Medical Sciences (CIOMS) in
collaboration with the World Health Organization (WHO). The
baseline screening program was approved by Sun Yat-sen Medical
University Cancer Center (later the Sun Yat-sen University
Cancer Center). We promised to fully inform the subjects of
possible adverse reactions, risk, discomfort and inconvenience
during the screening study, and as well as treatment program with
a possible compensation package. We made sure that all of the
participants in this screening program were voluntary, and the
subjects’ medical documents (including the demographic data,
testing results and diseases) to be saved securely. Permission to use
the data from the screening program as well as further follow-up
has been granted by the Institutional Ethics Review Board of Sun
Yat-sen Medical University Cancer Center (No. YP2009169). Any
published reports involved in the study wouldn’t reveal the
subjects’ identification.
Serologic Analysis
Each participant was asked to donate a 3 ml blood sample,
which was collected into one Vacutainer tube without heparin.
Blood samples were allowed to stay at room temperature for a
maximum of 6 hours before being processed in a laboratory.
Serum samples were then separated, divided into two tubes and
stored at 220uC at the local hospital. One week after collection,
sera were transported to Sun Yat-sen University Cancer Center
(SYSUCC). All tests were performed in the laboratory of
SYSUCC. EBV-specific VCA/IgA antibodies were measured
using an immunoenzymic assay described previously [42]. Those
with VCA/IgA titer $1:5 were defined as seropositive group, and
their levels of antibodies were further classified into four sub-
groups (1:5, 1:10, 1:20, $1:40) according to the maximum dilution
of serum. For the seropostive group, the EBV specific EA/IgA
antibody levels were further measured using an immunoenzymic
assay by Raji cell line [57]. Then the subjects were informed of the
serological test results and advised for regular follow-up tests to
examine the fluctuation of VCA/IgA and EA/IgA antibodies. The
follow-up tests were performed every year for a total of up to 10
times during 1988 and 1999 (Figure 4). In SYSUCC, a regular
quality control procedure for the assays has been used since 1980s
[58–59]. Briefly, in order to ensure the reliability of the serological
results, we used a pooled serological sample as our control sample.
The coefficient of variation (CV) of the assay over 8 years (1993–
2000) for VCA/IgA and EA/IgA was 8.37% and 8.47%,
respectively.
Definition of Antibody Fluctuation Pattern
In total, among subjects who were seropositive at recruitment
(1,318), 962 (73.0%) had undergone at least 2 repeated follow-up
tests during the first 5 years of follow-up. We further classified
them into three subgroups, i.e. Ascending, Stable or Descending,
by using the first three VCA/IgA results (Figure 5). Subjects whose
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19100Figure 4. Protocol of Serological Tests for Anti-Epstein-Barr Virus Antibodies in the Nasopharyngeal Carcinoma Screening Cohort
from 1987 to 2007 in Sihui, Guangdong, China.
doi:10.1371/journal.pone.0019100.g004
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previous test and the titers in the 3rd test were higher than the
baseline were classified into Ascending group (129 subjects).
Subjects whose repeated antibody titers were equal or lower than
those in the previous test and the titers in the 3rd test were lower
than the baseline were classified into Descending group (407
subjects). The rest were classified as Stable group (426 subjects).
Follow-up and Identification of Nasopharyngeal
Carcinoma Cases
In Sihui County, a cancer registry was established in 1978,
based on a three-level cancer prevention network, which was
described previously [3]. Cancer cases were reported by local
general practitioners, who provide health care for residents in
villages, to the regional hospital of each town (approximately once
each month). And then, health specialists assigned by Sihui Cancer
Research Institute collected the reports and recorded information
into pre-designed cards. For each incident cancer case, informa-
tion collected includes registration identification number (ID),
medical ID, Chinese Identity Card Number (unique for each
resident), ICD code (9th or 10th version), name, sex, birth date,
occupation, ethnicity, residence address, phone number, cancer
site, base of diagnosis, and pathological report if available (date of
diagnosis, names of hospital and physician in-charge). To ensure
the completeness of cancer report, death certificates provided by
the local public security bureau and hospitals were also reviewed.
The percentage of ‘death certificate only’ cases was 5% during
1987–2007. Up to 90.3% of NPC cases were diagnosed by
pathohistological review [3].
Furthermore, for correct censoring, dates of death were
obtained from the Causes of Death Register and the Rosters of
Village Committee, and dates of emigration came from the local
public security bureau and the Rosters of Village Committee.
Statistical Analysis
Person-years of follow-up for each cohort member were counted
from the date of one year after recruitment to the date of NPC
diagnosis, date of death or emigration, date of loss for follow-up, or
December 31, 2007, whichever occurred first. Age-adjusted
incidence rates by gender, area of residence and baseline EBV
serological antibodies were standardized to distribution of person-
time experienced by the entire cohort (5-year age groups). Kaplan-
Meier method was used to derive the cumulative probability of
NPC occurrence by baseline serostatus for VCA/IgA antibodies.
Hazard ratios (HRs) and their corresponding 95% confidence
intervals (95% CIs) derived from Cox proportional hazards
regression models were employed to explore the association
between baseline EBV VCA/IgA and EA/IgA antibodies and the
risk of NPC. The assumption of proportional hazards was tested
using graphical method as well as the method based on
Schoenfeld’s residuals [60]. It was indicated that this assumption
was not met for follow-up duration, as well as for age at entry and
Figure 5. Graph of displaying different fluctuation patterns in 962 subjects seropositive for baseline VCA-IgA test and with at least
2 repeated tests during the first 5 years of follow-up. The red arrow shows that titers of VCA/IgA were higher than those in the previous test.
The blue arrow shows that titers of VCA/IgA were equal to those in the previoust test. The green arrow shows that titers of VCA/IgA were lower than
those in the previous test. Therefore, according to the definition, 129 (21+70+38) subjects were classified into the Ascending group, 407 (72+279+56)
into the Descending group and 426 (178+26+222) into the Stable group. VCA/IgA, IgA antibodies against EBV capsid antigen; EA/IgA, IgA antibodies
against EBV early antigen. Definition: Ascending group: Subjects whose repeated antibody titres were equal or higher than those in the previous
test and the titres in the 3rd test were higher than the baseline. Descending group: Subjects whose repeated antibody titres were equal or lower
than those in the previous test and the titres in the 3rd test were lower than the baseline. Stable group: The rest of subjects.
doi:10.1371/journal.pone.0019100.g005
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attained follow-up duration (#5v s.5 years), and adjusted for sex
(as covariate in the regression model), age at entry, and area of
residence (as stratification variables).
In total, 7,890 subjects had undergone at least two serological
tests for EBV VCA/IgA antibodies. Therefore, to account for
time-varying exposure status, time-dependent Cox proportional
hazards regression models were used to explore NPC risk in
association with EBV infection. The first model used repeated
serological test results as time-varying variables. To quantitatively
measure the effect of antibody fluctuation on NPC risk, the second
model included baseline measurement as constant variable, and
the differences between each repeated test and baseline measure-
ment as time-varying variables. The difference was calculated as,
log2(maximum dilution of the repeated test) – log2(maximum
diluation of the baseline test).
Geometric means of antibody titers at baseline and at each year
of follow-up were calculated for baseline seropositive subjects to
display the variation of antibody titers over time. Moreover, to
explore the relation between fluctuant pattern of EBV-specific
VCA/IgA antibodies and the risk of NPC, we classified 962
subjects seropositive for baseline VCA-IgA tests and with at least 2
repeated tests during the first 5 years of follow-up, into 3
subgroups according to different fluctuant patterns, i.e. ‘‘Ascend-
ing’’, ‘‘Stable’’ or ‘‘Descending’’ (Figure 5). Cox proportional
hazards regression model was used to analyze the relation between
fluctuant type and NPC risk, using 17,093 subjects seronegative for
VCA/IgA at baseline as reference group. Cox proportional
hazards regression model was also used to calculate the relative
risk of NPC in association with seroconversion for VCA/IgA
positivity among 6,554 subjects who were seronegative for VCA/
IgA at baseline and had been retested for EBV antibodies in year
1997.
To evaluate the predictive performance of VCA/IgA and EA/
IgA, we employed the time-dependent receiver operating
characteristics (ROC) curve for censored data and the area under
the ROC curve (AUC) as the criterion [61–62]. Larger AUC
indicates better predictability of time to event. AUC of 0.5
indicates no predictive ability, whereas a value of 1 represents
perfect predictive ability. The ‘‘survivalROC’’ package for time-
dependent ROC curve estimation in the open-source statistical
software R (http://www.R-project.org) was used for the analysis.
All the statistical analyses, unless otherwise noted, were
performed using SAS version 9.2 (SAS Institute, Cary, NC,
USA). All statistical tests were two-sided, and a p value,0.05 was
considered as statistical significant.
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